产品
编 号：F314048
分子式：C24H16N6
分子量：388.42
分子式：C24H16N6
分子量：388.42
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
20mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 308362-25-6
产品详情
生物活性：
Ridinilazole is a novel antibacterial with MICs range of 0.06-0.25?μg/mL (MIC90=8?μg/mL) against C.?difficile.
体内研究：
In a hamster model of CDI with a once-daily dosing regimen, Ridinilazole displays greater efficacy than Vancomycin both against non-epidemic and epidemic strains of C.?difficile. Similar to the twice-daily dosing study, plasma levels of Ridinilazole are below the level of detection, whereas caecal Ridinilazole concentrations are well above the MIC, thus demonstrating the non-absorbable nature of Ridinilazole and minimal systemic exposure.
体外研究：
Ridinilazole is a novel antibacterial that does not appear to act through the classical pathways associated with antibiotics, such as inhibition of cell wall, protein, lipid, RNA or DNA synthesis. Ridinilazole may impair cell division. Ridinilazole is bactericidal against C.?difficile and exhibits a prolonged post-antibiotic effect. In susceptibility testing of 82 clinical isolates of C.?difficile (including ribotype 027), Ridinilazole displays potent growth inhibition and has lower MICs [MIC range, 0.06-0.25?μg/mL; MIC for 90% of the organisms (MIC90), 0.125?μg/mL] than Metronidazole (MIC range, 0.125-8?μg/mL; MIC90, 8?μg/mL) or Vancomycin (MIC range, 0.5-4?μg/mL; MIC90, 2?μg/mL). Similarly, Ridinilazole is found to be more potent than Metronidazole or Vancomycin at inhibiting the growth of 50 ribotype-defined C.?difficile strains. The activity of Ridinilazole against specific C.?difficile ribotypes (including ribotypes 001, 002, 005, 014, 027, 054 and 106) is similar, with an MIC range of 0.06–0.5?μg/mL and an MIC90 of 0.125?μg/mL. In addition, Ridinilazole is more active against 11 ribotype 027 strains than either Metronidazole or Vancomycin.
Ridinilazole is a novel antibacterial with MICs range of 0.06-0.25?μg/mL (MIC90=8?μg/mL) against C.?difficile.
体内研究：
In a hamster model of CDI with a once-daily dosing regimen, Ridinilazole displays greater efficacy than Vancomycin both against non-epidemic and epidemic strains of C.?difficile. Similar to the twice-daily dosing study, plasma levels of Ridinilazole are below the level of detection, whereas caecal Ridinilazole concentrations are well above the MIC, thus demonstrating the non-absorbable nature of Ridinilazole and minimal systemic exposure.
体外研究：
Ridinilazole is a novel antibacterial that does not appear to act through the classical pathways associated with antibiotics, such as inhibition of cell wall, protein, lipid, RNA or DNA synthesis. Ridinilazole may impair cell division. Ridinilazole is bactericidal against C.?difficile and exhibits a prolonged post-antibiotic effect. In susceptibility testing of 82 clinical isolates of C.?difficile (including ribotype 027), Ridinilazole displays potent growth inhibition and has lower MICs [MIC range, 0.06-0.25?μg/mL; MIC for 90% of the organisms (MIC90), 0.125?μg/mL] than Metronidazole (MIC range, 0.125-8?μg/mL; MIC90, 8?μg/mL) or Vancomycin (MIC range, 0.5-4?μg/mL; MIC90, 2?μg/mL). Similarly, Ridinilazole is found to be more potent than Metronidazole or Vancomycin at inhibiting the growth of 50 ribotype-defined C.?difficile strains. The activity of Ridinilazole against specific C.?difficile ribotypes (including ribotypes 001, 002, 005, 014, 027, 054 and 106) is similar, with an MIC range of 0.06–0.5?μg/mL and an MIC90 of 0.125?μg/mL. In addition, Ridinilazole is more active against 11 ribotype 027 strains than either Metronidazole or Vancomycin.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备